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ABSTRACT
Introduction: The available therapeutic strategies for Parkinson’s disease (PD) rely only on the ameli-
oration of the symptomatology of the disease, lacking neuroprotection or neuroregeneration capacities.
Therefore, the development of disease modifying strategies is extremely important for the management
10 of PD in the long term.
Areas covered: In this review, the authors provide an overview of the current therapeutic approaches
for PD and the emerging use of stem cell transplantation as an alternative. Particularly, the use of the
secretome from mesenchymal stem cells (MSCs), as well as some methodologies used for the modula-
tion of their paracrine signaling, will be discussed. Indeed, there is a growing body of literature
15 highlighting the use of paracrine factors and vesicles secreted from different cell populations, for this
purpose.
Expert opinion: Secretome from MSCs has shown its potential as a therapy for PD. Nevertheless, in the
coming years, research should focus in several key aspects to enable the translation of this strategy
from the bench to the bedside.
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20 1. Introduction
Parkinson’s disease (PD) is a chronic neurodegenerative dis-
order of insidious onset, characterized by the presence of
predominantly motor symptomatology such as bradykinesia,
rest tremor, rigidity, and postural disturbances [1]. These
25 motor deficits are the result of the progressive loss of dopa-
minergic (DAergic) neurons in the substantia nigra pars com-
pacta (SNpc) leading to the denervation of the nigrostriatal
tract and significant reduction of dopamine (DA) at the striatal
level [2,3]. Current theories on the etiology of PD consider this
30 disorder to be multifactorial and the result of a genetic pre-
disposition in combination with environmental factors. These
phenomena are thought to be responsible for the cellular
changes leading to progressive neuronal degeneration in
which oxidative stress, mitochondrial dysfunction, and failure
35 of the protein degradation machinery are probably involved.
One of the aims of the current PD research is to elucidate the
sequence in which they act and understand the interaction
between these pathways to develop effective neuroprotective
strategies for PD [4]. Indeed, the treatment for PD has not
40 changed substantially in the past 50 years, with DA replace-
ment therapy using levodopa (L-DOPA) as the mainstay [5].
However, its extended use, associated with the needs of
increased dosages, is linked with secondary side effects such
as nausea, vomit, hypotension, and long-term complications
45 including motor fluctuations and dyskinesias [6]. New drugs in
the form of DA agonists or enzyme inhibitors have been
developed to delay the need of L-DOPA therapy or to reduce
its dosage [7,8]. Moreover, surgical treatments, such as deep
brain stimulation (DBS) in the globus pallidus internus, or in
50the subthalamic nucleus, have been applied as an alternative
in patients with significant motor complications that no longer
respond to pharmacological approaches [9]. However, these
are all symptomatic approaches with no proven effect on
disease progression, imposing the need for innovative thera-
55peutic approaches.
Over three decades ago, several research groups have
devoted to the development of cell-based dopamine replace-
ment strategies [10]. While the capacity of human fetal ventral
midbrain (fVM) grafts to induce clinical improvement when
60transplanted into the human brain was being achieved and
evaluated, other cell sources including embryonic porcine
ventral mesencephalic tissue, autologous carotid body cells
or adrenal medullary tissue and human retinal pigmentary
epithelial cells underwent clinical trials. However, these trials
65were unsuccessful, maybe as a result of limited pre-clinical
data to support their use [10,11]. Regarding the use of fVM
allografts, they proved to be effective just in certain patients.
This inconsistency is justified by differences in tissue prepara-
tion, patient selection or also surgical method, among other
70factors [11]. However, these studies contributed to further
knowledge that enabled the development of a new human
fVM trial in PD, the TRANSEURO, funded in 2009 by the
European Union. Although this strategy seems promising, it
is not a realistic option for large-scale applications, in which
75a cell source that is easily stored, available and self-renewable
is more advantageous. Therefore, stem cells emerged as an
attractive alternative [10]. Among stem cell populations, the
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use of human embryonic stem cells (hESCs) (NCT019636),
induced pluripotent stem cells (iPSCs), or neural stem cells
80 (NSCs) (NCT02452723) to create DA neurons to restore the
function of brain affected regions are some of the most pro-
mising cell sources to replacement strategies [12]. Other
approaches have explored the use of non-ectodermal origin
stem cells, such as mesenchymal stem cells (MSCs). Indeed,
85 the use of these cells for regeneration purposes in different
neurological disorders have been extensively studied [13].
However, the approach vary according to the disease and is
completely different for PD and Huntington disease (HD) in
comparison with stroke or traumatic brain injury (TBI) [14,15].
90 At the onset of PD and HD a considerable number of neurons
are already lost. Therefore, a regenerative therapy in this con-
text will potentially stimulate the differentiation of new cells
for the replacement of the ones that are already dead. In the
particular case of PD, a reactivation of cells that are still viable
95 but dysfunctional or in a dormant phase might also happen
[16]. On the other hand, a regenerative cell therapy for stroke
or TBI is normally administered in an acute©stage with the
purpose of attenuating the inflammation process, which is
a characteristic of this stage [15]. Therefore, in these diseases,
100 the regenerative therapy would have a more protective role
upon the cells that are still viable.
Even though much effort has been applied to the develop-
ment of cell therapies, we still lack a clinically competitive
treatment for people with PD. Currently, according to the US
105National Institutes of Health website http://www.ClinicalTrials.
gov, there are two active (not recruiting) clinical trials using
cells in the context of this disease. Seven are recruiting (phases
I or II), involving the use of MSCs, neural precursor cells
derived from fetal mesencephalic or hESCs, human partheno-
110genetic neural stem cells, and bone marrow-derived stem
cells. Regarding the finished studies, four were completed
(Table 1), one was withdrawn (company was dissolved),
other one was terminated due to difficulties in recruiting the
adequate number of patients timely. Lastly, one study was
115completed but denoted as ‘terminated’ (Table 1).
For the application of the generated DAergic neurons in
a clinical setting, pre-clinical trials should demonstrate that
these cells: i) can survive in large numbers upon transplanta-
tion; ii) are able to effectively reinnervate the nigrostriatal
120tract; iii) have the capacity for axonal outgrowth and DA
release; and iv) lead to behavioral improvements in animal
models of PD [17]. Moreover, in such a disease in which its
pathogenesis is still unclear, experimental work is mandatory
to answer to specific questions such as the correlation of age
125and PD or which is the role of Lewy Bodies in the initiation or
progression of the disease, in order to uncover molecular
targets for innovative treatments. Therefore, investment in
the generation of pre-clinical data should be pursued to
develop clinical studies with stronger evidence of clinical ben-
130efits and demonstrated mechanisms of action.
A recent paradigm shift has emerged suggesting that the
beneficial effects of stem cells may not be restricted to cell
transplantation/differentiation alone but could be mediated
by the secretion of bioactive molecules, which nowadays is
135referred as secretome [18]. This could be advantageous when
compared to the cell-replacement strategies. Indeed these
latter still present several drawbacks, namely the need of to
obtain high number of cells to compensate for their low rate
survival after transplantation, the possibility of eliciting an
140immune response if allogenic cells are used and the uncertain
destiny of systemically administered cells [19–21].
Cells’ secretome includes a broad repertoire of trophic
factors, immunomodulatory cytokines, lipids, and extracellular
Article highlights
● The available therapeutic strategies for Parkinson’s disease do not
impact disease progression, imposing the need for innovative ther-
apeutic approaches.
● The use of stem cells has emerged as a promising approach for
regenerative medicine.
● Cell sources such as embryonic stem cells, induced pluripotent stem
cells, neural stem cells, or mesenchymal stem cells are some of the
most promising to replacement strategies.
● The secretome of some cell populations is now accepted as their
main therapeutic action.
● The secretome can be modulated at intracellular and extracellular
levels with the purpose to potentiate its benefits.
● The potential of the secretome in Parkinson’s disease©encourages the
development of cell-free products over cell transplantation strategies.
This box summarizes key points contained in the article.
Table 1. Clinical approaches using potential cell therapies for PD regeneration. (PD = Parkinson’s disease; DBS = deep brain stimulation).
Therapy Aim of the study Comments
ClinicalTrials.
gov identifier
Active (not
recruiting)
Stereotactic intraputaminal implantation of human
allogeneic fetal derived stem cells
Safety trial pathology
of the disease
Phase I ongoing NCT02780895
Xenotransplantation of immunoprotected (alginate-
encapsulated) porcine choroid plexus cells
Safety and effect on
progression of PD
Phase II ongoing NCT02683629
Completed Embryonic dopamine cell implant surgery Effect on progression
of PD
Phase III: clinical benefit and graft viability
sustained up to 4 years after transplantation
NCT00038116
Transplantation of fetal porcine cells Safety and effect on
progression of PD
Phase II (no posted conclusions) NCT00226460
Xenotransplantation of immunoprotected (alginate-
encapsulated) porcine choroid plexus cells
Safety and effect on
progression of PD
Phases I/II (no posted conclusions) NCT01734733
Implantation of peripheral nerve graft during DBS
surgery
Safety data for a larger
phase clinical trial
Pilot study: feasible and safe delivery of the
graft; possible clinical benefit
NCT01833364
Bilateral implantation of cultured human retinal
pigment epithelial cells on microcarriers
Safety and effect on
progression of PD
Phase II: no advantage over sham surgery for
advanced PD
NCT00206687*
* Completed study but registered as terminated, because lifelong extended follow-up phase was discontinued after 12 years.
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vesicles, which in turn have multiple implications in the reg-
145 ulation of key biologic processes such as neuroprotection (e.g.
protecting cells from oxidative stress), neurodifferentiation, as
well as regulation of inflammatory processes [22]. Here, we
specifically highlight the current understanding regarding the
use of NSCs, glial cells and MSCs as natural sources or as
150 vehicles for the delivery of neurotrophic factors in the context
of PD. Moreover, we review recent experimental data addres-
sing different methodologies being used for an efficient and
high-quality secretome production.
2. Therapeutic strategies for PD based on cell
155 secretome
2.1. Neural-derived cells
Neural stem cells are the obvious candidates for cell transplan-
tation strategies due to their ability to self-renew and differ-
entiate into neurons. Besides the graft-derived functional
160 effects when transplanted into the striatum of 6-hydroxydo-
pamine (6-OHDA)-lesioned rats, Yasuhara and colleagues [23]
further demonstrated the neuroprotective effects of these
cells mediated by trophic factor secretion.
Recent work from our lab as shown that the injection of the
165 secretome of human neural progenitor cells (hNPCs) in the
SNpc and striatum of a 6-OHDA rat model of PD stimulated
the recovery of DAergic neurons, resulting in an improvement
of the motor behavior [24]. Moreover, the improvement in
DAergic neurons survival and motor deficits was superior in
170 the groups that were injected with secretome in comparison
to the groups not treated or those transplanted with hNPCs.
The characterization of the secretome revealed the presence
of different players, such as brain-derived neurotrophic factor
(BDNF) or pigment epithelium-derived factor (PEDF), which are
175 known to have important functions in DAergic neuronal pro-
tection and survival [24].
Several studies have also demonstrated the effects of glial
cells in the context of PD. Microglia secretome, and particu-
larly the fraction of the medium containing molecules below
180 30 kDa, was shown to protect cerebellar granule neurons from
6-OHDA neurotoxicity, mainly attributed to the release of TGF-
β2 [25]. The secretome of olfactory ensheathing cells (OECs),
a special population of glial cells that ensheath the axons of
the olfactory receptor neuron, was also shown to prevent
185 apoptosis induced by 6-OHDA in PC12 cells [26]. This effect
was mediated by the modulation of intrinsic apoptotic path-
ways, via up-regulation of Bcl-2, down-regulation of Bax, and
thus attenuation of mitochondrial transmembrane potential
loss, which inhibited apoptosis [26].
190 To increase the neuroprotective effects of glial cells’ secre-
tome, other authors have modulated the expression of neuro-
trophic factors in the glial cells. For instance, the secretome of
astrocytes overexpressing glial cell line-derived neurotrophic
factor (GDNF) led to a resistance against 6-OHDA toxicity in
195 a growing neuronal cell line (SK-N-MC) [27]. Biju and collea-
gues [28] have also demonstrated the amelioration of 1-metil-
4-fenil-1,2,3,6-tetraidropiridina (MPTP)-induced degeneration,
synaptic marker staining and functional recovery after sys-
temic administration of bone-marrow derived microglia
200expressing neurturin. The authors support the use of microglia
as a source of sustained local delivery of neurturin, due to
their ability to cross the blood brain barrier. In a recent study,
OECs overexpressing nuclear receptor-related factor 1 and
neurogenin 2 increased the viability of PC12 cells treated
205with the neurotoxin MPP+ (1-methyl-4-phenylpyridinium),
inhibited oxidative stress and apoptosis in vitro, and amelio-
rated the behavioral deficits in a 6-OHDA rat model co-
transplanted with ventral mesencephalic cells [29].
2.2. Mesenchymal stem cells
210MSCs are a population of adult multipotent cells with the
ability to self-renew and differentiate into mesenchymal
lineages, with strong immunomodulatory activities [30].
These cells can be easily isolated from different sources,
including bone marrow, adipose tissue, dental pulp, and umbi-
215lical cord Wharton’s Jelly (WJ), which prompt several authors
to explore their use in cell transplantation strategies for PD
[31–33]. The first report of MSCs’ potential for PD recovery
demonstrated a behavioral recovery in apomorphine-induced
rotations after WJ-derived MSCs (WJ-MSCs) transplantation in
220the striatum of a hemiparkinsonian rat model, suggesting
trophic factor secretion as a mediator of the rescue of the
degenerating DAergic neurons in the substantia nigra and
ventral tegmental area (VTA) [31]. Intravenous administration
of rat bone marrow-derived MSCs (BM-MSCs) has also signifi-
225cantly ameliorated the functional deficits and preserved tyro-
sine hydroxylase (TH)-positive fibers in the striatum and TH-
positive neurons in the SNpc in a 6-OHDA rat model [33]. After
detecting SDF-1α in the secretome of MSCs, the authors
demonstrated that this chemotactic cytokine suppressed
230apoptotic cell death of 6-OHDA-exposed PC12 cells with con-
sequent increase of DA release from the cells [33]. Cova and
colleagues [32], have also demonstrated that human MSCs
(hMSCs) transplantation in the striatum of 6-OHDA lesioned
animals, five days after the toxic insult, protected the DAergic
235terminals and induced neurogenesis in the subventricular
zone, suggesting that hMSCs in situ may provide an effective
support to injured neurons through the local release of solu-
ble factors, such as BDNF.
Despite the previous reports that establish the potential
240of MSCs as a therapeutic tool for PD, none of them demon-
strated the acquisition of a neuronal phenotype of grafted
cells, and thus put forward the secretion of neurotrophic or
anti-apoptotic factors as mediators of neuroprotection. In
line with this, our group showed that the secretome of
245mesenchymal progenitors from the human umbilical cord,
besides inducing neuronal differentiation of human telence-
phalon neural precursor cells, it was able to stimulate the
levels of proliferation, neuronal/glial survival and differentia-
tion when injected in the rat hippocampal dentate gyrus in
250a similar way to the transplantation of cells [34]. Other
authors explored the use of MSCs secretome (in the form
of conditioned media) as a cell transplantation-free
approach for PD. In vitro studies revealed the neuroprotec-
tive effect of the secretome collected from human BM-MSCs
255(hBM-MSCs) and human tooth germ stem cells, in 6-OHDA
induced cytotoxicity of murine differentiated neural stem
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cells and SH-SY5Y cells [35,36]. Parga et al. [37] have also
explored the viability of DAergic cells from different sources
in response to rat BM-MSCs secretome, unveiling prostaglan-
260 din E2 receptors as main mediators of the observed neuro-
protective and neurorescue activities. Additionally, our
group© has© also investigated the in vivo effects of hBM-
MSCs secretome, showing a behavioral recovery of 6-OHDA
lesioned rats supported by an increase of DAergic neurons
265 and neuronal terminals in the SNpc and striatum, respec-
tively. Based on the proteomic analysis of the secretome, we
found that BM-MSCs secreted not only important neuro-
trophic factors, such as vascular endothelial growth factor
(VEGF), BDNF, interleukin-6 (IL-6) and GDNF, but also other
270 potential neuroregulatory molecules, namely cystatin C (Cys
C), glia-derived nexin, galectin-1, and PEDF [38]. Recently, it
was also demonstrated the ability of MSCs secretome to
degrade extracellular α-synuclein both in vitro and in vivo,
an effect partially mediated by matrix metalloproteinase-2
275 (MMP-2) [39].
Another important therapeutic use of MSCs secretome for
PD©is its combination with cell replacement strategies. Shintani
and colleagues [40], demonstrated that pretreatment of
embryonic DAergic neurons with rat BM-MSCs secretome
280 increased their survival after grafting in a 6-OHDA rat model
of PD. Yao and colleagues [41] have also reported a reduction
of apomorphine-induced rotational asymmetry and improved
spatial learning after transplantation of secretome-treated
neural stem cells into PD rats, which was correlated with an
285 increased cell survival and differentiation into DAergic neu-
rons in the VTA.
Recently, the contribution of the MSCs-secreted vesicles for
paracrine-mediated regeneration has also been investigated
[42]. In the context of PD, Jarmalavičiūtė and colleagues [43]
290 have demonstrated that exosomes isolated from dental pulp
stem cells rescued human DAergic neurons from 6-OHDA
induced apoptosis. Nevertheless, this is a growing area of
research, and thus more studies are required to assess the
role of exosomes in the reported effects of MSCs secretome.
295Other authors have modulated MSCs secretion of neuro-
trophic factors, either by neurotrophic exposure [44] or over-
expression of a specific factor in MSCs. For instance, the
transplantation of GDNF-transduced rat BM-MSCs was shown
to induce protection and sprouting of DAergic terminals in the
300striatum of neurotoxin-induced and inflammation-induced rat
PD model [45,46]. Human umbilical cord-MSCs transduced
with hepatocyte growth factor (HGF) were also able to regen-
erate SH-SY5Y cells exposed to MPP+, an effect probably
achieved through the regulation of intracellular Ca2+ by mod-
305ulating the expression of CaBP-D28K, an intracellular calcium-
binding protein [47].
3. Modulation of cell secretome profile
Cell plasticity is one of the most important characteristics that
makes some cell populations (e.g. MSCs) a potential therapeutic
310tool for central nervous system (CNS) applications [48–52].
Indeed, the capacity to adapt and grow into different culture
conditions indicates that MSCs could be able to change/mod-
ulate their own secretome according with the conditions in
which they are cultured [53–55]. Besides the secretome mod-
315ulation at the intracellular level, the modulation of external cues
present in cells’ microenvironment and their impact on para-
crine signaling have also been explored (Figure 1). However, the
mechanisms underlying this modulation by the external envir-
onment are still unknown. Harnessing this knowledge would be
320extremely valuable to modulate the secretome according to the
context of the disease in which it would be applied. The culture
conditions can be changed regarding, for instance, oxygen
Figure 1. Strategies for the extracellular modulation of secretome from MSCs. The use of hypoxia conditions, bioreactors, hydrogels, scaffolds and spheroids has
been shown to stimulate the expression of certain factors with important roles in the CNS.
4 C. R. MARQUES ET AL.
tension [56] and establishing dynamic cultures such as porous
scaffolds, spheroids, or their combination, as well as encapsula-
325 tion in hydrogels or even inside bioreactors [57]. Although
diverse studies examined the secreted factor production of
different cell types, most of recently published reports focus
on MSCs due to their widespread preclinical use for tissue
regeneration. Therefore, most of the concepts discussed in
330 this topic are based on MSCs culture conditions modulation
and their impact on trophic factors secretion.
3.1. Hypoxia
The oxygen tension present in the culture medium plays an
important role in the behavior of MSCs. MSCs are usually cul-
335 tured under normoxic conditions (21% O2). However, in the
human body, these cells are exposed to much lower concentra-
tions of oxygen. Oxygen levels of 21% have been linked to DNA
damage, leading to genomic instability and cellular senescence
[58]. Several studies have been reporting that exposure to
340 a hypoxic environment leads to changes in MSCs physiology,
such as increasing the release of VEGF, impacting cellular senes-
cence [59] cell proliferation or differentiation [60,61] and con-
sequently their regenerative potential [62].
The effects of a hypoxic environment may also influence
345 MSCs secretome profile. On this topic, our group showed that
hypoxic (5% O2) and normoxic conditions-induced alterations in
the secretome profile of WJ-MSCs which is translated in the
capacity of both secretomes to maintain cell viability and induce
differentiation of hNPCs. Furthermore, hypoxia led to the expres-
350 sion of 62 more proteins, when compared to normoxic culturing
conditions [63]. Yuan and colleagues [64] also reported changes
due to the exposure to 3% O2 in the secretion of VEGF, nerve
growth factor (NGF), BDNF, GDNF, and MMP-2. The authors
suggest that hypoxia effects are mediated by the hypoxia-
355 inducible factor-1, which is important for the transcriptional
activation of VEGF. In line with this, Ahmed and coworkers [65]
reported that hypoxia (5% O2) led to a significant increment in
the expression of VEGF, BDNF and NGF. In another study, Chang
and coworkers [66] administered secretome from hypoxic-
360 preconditioned MSCs in rats with traumatic brain injury and
saw that they performed significantly better in motor and cog-
nitive function tests, had significantly less brain damage, and
higher neurogenesis levels. Authors concluded that secretome
had higher expression levels of VEGF and HGF.
365 3.2. Bioreactors
Cells, specifically MSCs, are usually expanded in 2D or static
cultures, inside tissue culture flasks that provide a good gas
exchange and not only are cost-effective, but also easy©to
©operate. Nevertheless, if a larger number of cells are needed
370 for clinical applications, using the mentioned systems would
not be the most suitable methodology. For the scalable pro-
duction of MSCs or their secretome, the development of
a bioprocess that provides a controlled environment, where
physiological, nutritional, chemical, and mechanical require-
375 ments are well-defined and maintained, should be mandatory
[67]. Bioreactor systems can provide an interactive 3D micro-
environment through the regulation of the spatial distribution
of macromolecules and mechanical cues. Therefore, they have
the capacity to recreate the interactions between MSCs and
380their microenvironment [57,68].
Mechanical forces are capable of shaping MSCs’ fate and
bioreactors provide a tool to study the cellular response to
mechanical stimulation under controlled conditions [69].
Indeed, several studies used bioreactors to successfully stimu-
385late the differentiation of MSCs for different purposes [70–72].
MSCs grow inside the bioreactor as tissue aggregates or
adherent cells to microcarriers.
Different types of bioreactors have been used for the
expansion of MSCs, including stirred tank bioreactors, perfu-
390sion bioreactors, rotating well bioreactors and also microflui-
dic bioreactors [57,73]. However, few studies have addressed
the use of these systems to modulate the paracrine signaling
of MSCs for neurodegenerative purposes. Hupfeld and collea-
gues [74] studied the effects of the expansion process of MSCs
395derived from the amniotic membrane (AM) and from the
umbilical cord (UC) on their biological characteristics. The
authors concluded that the culture of MSCs in controlled
bioreactor systems led to less heterogeneity between cells
from different donors. These cells significantly differed from
400the cells cultured in flasks regarding surface markers, paracrine
factors and gene expression profiles. Interestingly, VEGF was
only secreted by UC-MSCs (also stimulated with cytokines)
which had been expanded in bioreactors. Similarly, AM-MSCs
cultivated in bioreactors secreted significantly higher levels of
405VEGF. Our group used computer-controlled stirred bioreactors
to modulate the secretome of hBM-MSCs [75]. We showed
that this system led to an enhancement of the neuroregula-
tory profile of hBM-MSCs secretome, which induced an
increased differentiation of hNPCs. When administered in
410rats, even though more notorious in dynamic secretome,
both secretomes induced proliferation and neuronal differen-
tiation. All of these findings can be related with the upregula-
tion in the dynamic secretome of important regulators/
modulators of the neurogenic and neural differentiation pro-
415cesses such as Cys C, glia-derived nexin, galactin-1, PEDF and
also BDNF, VEGF, NGF, and insulin-like growth factor 1.
Moreover, we identified more 28 specific molecules in the
dynamic secretome which can be, at least some of them,
molecules with a neuroregulatory potential.
4203.3. Culture within scaffolds or encapsulated in
hydrogels
One of the limitations of the administration of secretome per se©
is the impossibility of establishing a controlled release system.
Indeed, we saw that when secretome was administered in a rat
425PD model, the effects of the secretome decreased with time,
possibly due to in situ consumption [38]. In tissue engineering-
based approaches, one possible strategy to overcome this lim-
itation is the local injection of hydrogel-embedded MSCs,
enabling a long lasting secretome production with increased
430control over cell fate [76]. The use of biomaterials can be an
essential strategy [77], because 3D culture of MSCs within scaf-
folds or hydrogels impacts cell physiology, enhancing endogen-
ous extracellular matrix (ECM), and integrin expression while
promoting the secretion of trophic factors [57]. However, cell
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435 organization and functionality are influenced by the mechanical
properties of the biomaterial. Furthermore, these parameters
also depend on the surface properties and spatial distribution
of ECM molecules on the scaffolds and hydrogels [78]. In line
with this, our group has already shown that cell adhesive cues
440 present in 3D hydrogels regulate© cell paracrine response,
enhancing higher metabolic viabilities and neuronal cell densi-
ties [53]. Lee and colleagues [79] also concluded that the incor-
poration of carbon nanotubes within collagen hydrogels
promoted the secretion of neurotrophic factors, particularly,
445 NGF and BDNF. In another study, these neurotrophins were
only expressed by MSCs isolated from gingiva cultured in
a poly(lactic acid) scaffold [80].
Given that the size of the scaffolds can be restricted in
static culture, they can be combined with bioreactors to pro-
450 vide a controllable environment for cultured cells. These
dynamic systems should mimic cells’ microenvironment to
mobilize their full biological potential [81].
3.4. Culture as spheroids
Spheroids, or multicellular aggregates, are one of the simplest
455 methods of 3D culture, which allow enhanced cell–cell inter-
actions and better mimic the natural microenvironment of
a tissue [82]. These characteristics can be the reason for the
benefits obtained with this methodology. Indeed, spheroid
grown MSCs showed enhanced differentiation potential [83],
460 anti-inflammatory [84] and angiogenic properties [85], as well
as improved survival after transplantation and increased para-
crine expression [86]. This can be a simple approach to mod-
ulate the secretome of MSCs. Redondo-Castro and colleagues
[87] showed that culture of MSCs spheroids changed the
465 secretome of these cells leading to an enhanced secretion of
cytokines involved in tissue repair and modulation of inflam-
mation. Berg and coworkers [88] showed that spheroid cul-
tures of adipose-derived MSC displayed higher levels of
neurotrophic factors compared to adherent cultures, particu-
470 larly nerve growth factor receptor and GDNF and also the
integrin alpha subunit CD49b. However, the implementation
of spheroid cultures demands stirring, through the use of
bioreactors, or incorporation within biomaterials, to minimize
spheroid agglomeration, which is the cause for cell necrosis/
475 apoptosis or decreased cell proliferation [82].
4. Conclusion
PD is an incredibly complex and multifaceted disorder, affect-
ing millions of people worldwide. The nigrostriatal pathway,
which is involved in the fine modulation of motor function is
480 the anatomical circuit mostly affected in PD, due to the loss
of DAergic neurons at the SNpc [89]. The currently available
therapeutic options reflect the lack of understanding of the
causes of PD, as they are designed to minimize the motor
and non-motor symptomatology, by replacing the lack of DA
485 or increasing its activity/metabolism. Nevertheless, these
strategies fail at a long-term perspective as they lose their
therapeutic effect over time, leading to the use of higher
dosages, which has been associated with undesirable side
effects [90]. Several groups have been focusing their research
490on disease-modifying strategies, able to prevent, slow or halt
the progression of PD. The use of stem cells has emerged as
a promising approach for regenerative medicine and several
debilitating disorders, due to their capacity to rapidly prolif-
erate, self-renew, and differentiate [91]. In this field, both
495ectodermal-origin and non-ectodermal origin stem cells
have been explored in stem cell-based strategies. However,
the secretome of some cell populations and their paracrine
activity on other neighboring cells is now accepted as their
main therapeutic action [21]. This acknowledgement
500together with the ethical and technical concerns associated
with cell transplantation, constitute valid reasons to foment
the research on the characteristics and applications of
secretome.
In this review, studies that explored the potential of the
505secretome from neural-derived cells and MSCs in the context
of PD were reported (Figure 1). Although much has been done
to demonstrate the effectiveness of the secretome from differ-
ent sources, a complete description of its mechanism of action
is still missing. This could be justified by the lack of a clear
510definition about which fraction (soluble or vesicular) is mediat-
ing the evident benefits of the secretome or if they act together
as a whole. Regarding the soluble fraction of secretome, the
knowledge gathered until now suggests that some of its mole-
cules, with important roles in the CNS, may act together or
515singly to exert their therapeutic effects (Figure 2). The charac-
terization of the secretome of undifferentiated hNPCs through
a proteomic analysis© enabled the identification of several
important molecules with neuroregulatory potential, namely,
GDNF, BDNF, PEDF, Cys C, and also DJ-1, among others [24].
520Different studies have been developed to ascertain their roles.
The results indicate that all of these molecules display neuro-
protective actions in the CNS through, for instance, the activa-
tion by GDNF of signaling pathways such as the mitogen-
activated protein kinase (MAPK) or the protein kinase B, indu-
525cing the inhibition of pro-apoptotic molecules like JNK or p38
[92]. In line with this, DJ-1 modulates the levels of miR-221 in
part through the activation of the MAPK/extracellular-regulated
kinase pathway. miR-221 also downregulates the©expression of
pro-apoptotic proteins [93]. Moreover, PEDF stimulates the acti-
530vation of the nuclear factor NF-κB signaling cascade, leading to
the expression of BDNF and GDNF [94]. In a mice model expres-
sing human-mutated α-synuclein, Cys C upregulated VEGF and
autophagy and downregulated α-synuclein and apoptosis dis-
playing, consequently, a neuroprotective effect [95]. In another
535characterization study developed by our team, VEGF was also
identified in the secretome of MSCs, together with some of the
proteins secreted by NPCs like GDNF, BDNF, PEDF, Cys C, DJ-1,
and other molecules such as IL-6 and MMP-2 [38,96]. VEGF plays
a protective role in DAergic neurons either through direct
540mechanisms, like the activation of the neuropilin receptor
expresses on DAergic neurons or indirectly by the promotion
of angiogenesis, increasing vessel permeability or enhancing
both glial proliferation and secretion of neurotrophic factors
[97]. IL-6 may also protect DAergic neurons through signal
545transducers and activators of transcription pathways, leading
to the increment of antioxidant enzyme activity and reactive
oxygen species scavenging [98].
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The presence of abnormal aggregates of α-synuclein,
known as Lewy bodies, in cell bodies and processes of
550 neurons are one of the hallmarks of PD and might result
in the disruption of different cellular functions involving the
mitochondria, lysosomes, endoplasmic reticulum and Golgi
or also the nucleus [99]. As previously mentioned, MMP-2
may partially mediate the degradation of α-synuclein aggre-
555 gates [39]. Another study showed that the secretome of BM-
MSCs had a neuroprotective effect in α-synuclein-enriched
cellular and animal models, due to the induction of M2
microglia polarization (considered anti-inflammatory and
constituted by phagocytic cells), which enhanced α-
560 synuclein clearance. The authors concluded that interleu-
kin-4, secreted by MSCs, was the mediator of this
effect [100].
MSCs have been extensively explored not only as a cell-
therapy strategy, but also as a source of secretome with
565 important applications for neurodegenerative diseases and
other conditions. The understanding that MSCs respond to
alterations in their microenvironment, for instance, those
induced by dynamic culture conditions, changing their
paracrine profile, has led to the development of strategies
570 to modulate their secretome. In this regard, recent
approaches that took advantage from this feature were
reviewed. Essentially, by decreasing the oxygen tension
or by establishing dynamic cultures through the use of
bioreactors, biomaterials or spheroid cultures, these strate-
575gies led, generally, to the upregulation of certain key
molecules with important roles in the proliferation, survi-
val, migration, and differentiation of cells in the nervous
system.
The knowledge gathered until know regarding the efficacy
580of the secretome in animal models of PD, encourages the
development of cell-free products, eliminating the need for
cell transplantation strategies. Nevertheless, before the accep-
tance of secretome as a clinically viable option for regenera-
tive therapies, different hurdles must be overcome. To fully
585harness the potential of secretome, the best strategies to
efficiently modulate the secretome should be defined.
Moreover, they must be easily reproducible and enable
a large-scale production. Moreover, to better understand the
effects and mechanism of action of secretome and translate
590this knowledge into clinically relevant results, more robust
in vitro and in vivo models are necessary. Furthermore, other
practical considerations such as mode of administration,
dosage, timing and safety must also be addressed prior to
clinical integration.
595Cells’ secretome represents a promising alternative to cell-
based regenerative medicine therapies. However, beyond the
great enthusiasm regarding this approach, much investigative
work must be developed to build a robust and customized
secretome-based therapy for PD.
Figure 2. Overview of the impact of secretome from neural-derived cells and MSCs on different aspects relevant in the context of PD and the secreted factors that
are mediating these effects. Several factors are present in cells’ secretome, namely exosomes, enzymes (MMP-2), hormones, cytokines (SDF-1α, IL-6, TGF-β2) and
growth factors (BDNF, GDNF, VEGF, neurturin). α-syn = α-synuclein; BDNF = brain-derived neurotrophic factor; GDN = glia-derived nexin; GDNF = glial cell line-
derived neurotrophic factor; IL-6 = interleukin 6; MMP-2 = matrix metalloproteinase 2; MSCs = mesenchymal stem cells; NPCs = neural progenitor cells; Nurr1/
NG2 = nuclear receptor-related factor 1 and neurogenin 2; OECs = olfactory ensheathing cells; SDF-1α = stromal cell-derived factor 1; TGF-β2 = transforming growth
factor-beta 2; TH+=tyrosine hydroxylase positive; VEGF = Vascular endothelial growth factor; +=overexpression.
EXPERT OPINION ON BIOLOGICAL THERAPY 7
600 5. Expert opinion
Satisfactory approaches to relieve©or to slow down PD are still
missing. While important gains were achieved with the current
pharmacological/surgical treatments in the quality of life of PD
patients, they have failed to arrest PD progression and do not
605 promote DAergic neurons protection or differentiation.
Therefore, there is an urgent need for the development of
novel antiparkinsonian strategies with specific neuroprotective
and neuroregenerative effects on the dopaminergic system. In
recent years, new concepts mainly focused on neuroprotec-
610 tive/disease-modifying actions have promisingly emerged for
the treatment of PD, such as the use of stem cell-based
strategies. Within them, MSCs and their secretome has been
presented as a promising therapeutic option. Indeed, studies
have shown that the administration of secreted factors and
615 vesicles leads to the protection of DAergic neurons and animal
behavior improvement (of PD rat models), most likely due to
the activation or modulation of endogenous neuro-restorative
pathways. Therefore, while transdifferentiation and cell fusion
remains still a (elusive) potential mechanism behind the
620 regenerative capacity of MSCs, its secretome arises nowadays
as the most likely candidate. In fact, the use of the secretome
instead of cell transplantation can be more advantageous,
proving to be an easily cryopreserved product, even in very
small volumes, without recurrence to cryopreservation solu-
625 tions, exhibiting a high stability after thawing. These charac-
teristics make the MSCs secretome a ‘ready-to-use’ product,
which is a very important feature when speaking about hos-
pital routine regarding daily administration of treatments in
patients.
630 Despite the identification of several factors within the
secretome with the capacity to induce neuronal cell growth,
survival and differentiation, the challenge remains regarding
the full characterization of MSCs secretome. Additionally,
another question that is still unanswered is, if the enthusiastic
635 outcomes seen so far are the result of one or two factors or
the result of the combination/interaction between all of the
factors present in the secretome. Lastly, studies reporting
improvement in animal behavior in PD animal models rely
on intracranial injections to deliver the secretome. What
640 about intraperitoneal or intravenous administrations? Would
the outcome be the same?
While in animal models the secretome has proven to par-
tially revert the phenotype of the disease, the doubt regarding
its ability to reach the clinical setting remains. To approach
645 such assumption, new protocols for the production of high-
quality secretome under good manufacturing practices guide-
lines should be developed. In this regard, bioreactors consti-
tute an important tool to the large-scale production of
secretome under controlled conditions, avoiding variability
650 between batches and enabling the establishment of MSCs
secretome as an off-the-shelf product.
Given that the number of MSCs in the human body
decreases with age and that the techniques for their isolation
are considered invasive, expensive, and labor-intense, research
655 on the most suitable source of MSCs must be fostered. One
possible alternative could be the use of patient-specific
induced MSCs (iMSCs) derived from iPSCs.
We consider that in the coming years, research will be pur-
sued to answer©the aforementioned topics. Among them, we
660believe that for their importance, full characterization of the
secretome and modulation strategies will receive particular
attention. Indeed, these are two areas in which we are develop-
ing our work, together with the derivation of iMSCs from iPSCs.
Attending to the epidemiology and the characteristics of
665the disease, there is an urgent need for alternative therapeutic
approaches for PD. The research on the development of cell
secretome as a disease modifying strategy can have an impact
on the progression of the disease by slowing it down through
the protection of DAergic neurons from premature death.
670Furthermore, the secretome might be used as a potential add©-
on to PD symptomatology therapies, as well as a vehicle in cell
transplantation strategies to increase the survival and viability
of transplanted (un)differentiated cells.
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